MMSL 2025, 94(1):27-36 | DOI: 10.31482/mmsl.2024.001

ATHEROSCLEROTIC CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASEReview article

Ondřej Kučerka ORCID...1,2, Martin Malý ORCID...1, Petra Mináriková ORCID...1, Jan M. Horáček ORCID...2,3*
1 Department of Medicine, First Faculty of Medicine, Charles University and Military University Hospital Prague, Czech Republic
2 Department of Military Internal Medicine and Military Hygiene, Military Faculty of Medicine, University of Defence, Hradec Králové, Czech Republic
3 Department of Internal Medicine IV – Hematology, University Hospital and Faculty of Medicine, Charles University, Hradec Králové, Czech Republic

Inflammatory bowel disease (IBD) is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). This article reviews the epidemiology, pathophysiology, risk factors and treatment implications of ASCVD in IBD patients. A number of processes are involved in the increased risk of ASCVD, including inflammation, endothelial dysfunction, hypercoagulability, platelet abnormalities, dyslipidaemia, gut microbiome abnormalities and the use of corticosteroids. While the precise pathophysiology remains complex, the management of inflammation and cardiovascular risk factors is essential to reduce the risk of atherosclerosis in IBD patients. Collaboration between gastroenterologists and preventive cardiologists is emphasised for risk factor management and promotion of disease remission.

Keywords: cardiovascular disease; inflammatory bowel disease; chronic inflammation; atherosclerosis

Received: September 16, 2023; Revised: January 4, 2024; Accepted: January 16, 2024; Prepublished online: January 25, 2024; Published: March 3, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kučerka, O., Malý, M., Mináriková, P., & Horáček, J.M. (2025). ATHEROSCLEROTIC CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. MMSL, 94(1), 27-36. doi: 10.31482/mmsl.2024.001
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Timmis A, Vardas P, Townsend N, et al. European Society of Cardiology: cardiovascular disease statistics 2021. European Heart Journal. 2022;43(8):716-799. Go to original source... Go to PubMed...
    2. Libby P, Loscalzo J, Ridker PM, et al. Inflammation, Immunity, and Infection in Atherothrombosis. Journal of the American College of Cardiology. 2018;72(17):2071-2081. Go to original source... Go to PubMed...
    3. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis & Rheumatism. 2008;59(12):1690-1697. Go to original source... Go to PubMed...
    4. Feng W, Chen G, Cai D, et al. Inflammatory Bowel Disease and Risk of Ischemic Heart Disease: An Updated Meta-Analysis of Cohort Studies. JAHA. 2017;6(8):e005892. Go to original source... Go to PubMed...
    5. Sun HH, Tian F. Inflammatory bowel disease and cardiovascular disease incidence and mortality: A meta-analysis. Eur J Prev Cardiolog. 2018;25(15):1623-1631. Go to original source... Go to PubMed...
    6. Bhardwaj A, Singh A, Midha V, et al. Cardiovascular implications of inflammatory bowel disease: An updated review. World J Cardiol. 2023;15(11):553-570. Go to original source... Go to PubMed...
    7. Massironi S, Mulinacci G, Gallo C, et al. The oft-overlooked cardiovascular complications of inflammatory bowel disease. Expert Review of Clinical Immunology. 2023;19(4):375-391. Go to original source... Go to PubMed...
    8. Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. 2020;5(1):17-30. Go to original source... Go to PubMed...
    9. Rungoe C, Basit S, Ranthe MF, et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut. 2013;62(5):689-694. Go to original source... Go to PubMed...
    10. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. European Heart Journal. 2010;31(8):1000-1006. Go to original source... Go to PubMed...
    11. Principi M, Mastrolonardo M, Scicchitano P, et al. Endothelial function and cardiovascular risk in active inflammatory bowel diseases. Journal of Crohn's and Colitis. 2013;7(10):427-433. Go to original source... Go to PubMed...
    12. Senchenkova E, Seifert H, Granger D. Hypercoagulability and Platelet Abnormalities in Inflammatory Bowel Disease. Semin Thromb Hemost. 2015;41(06):582-589. Go to original source... Go to PubMed...
    13. Agouridis AP, Elisaf M, Milionis HJ. An overview of lipid abnormalities in patients with inflammatory bowel disease. Ann Gastroenterol. 2011;24(3):181-187.
    14. Aron-Wisnewsky J, Clément K. The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nat Rev Nephrol. 2016;12(3):169-181. Go to original source... Go to PubMed...
    15. Dubois-Camacho K, Ottum PA, Franco-Muñoz D, et al. Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. WJG. 2017 ;23(36):6628-6638. Go to original source... Go to PubMed...
    16. Ross R. Atherosclerosis - An Inflammatory Disease. Epstein FH, editor. N Engl J Med. 1999;340(2):115-126. Go to original source... Go to PubMed...
    17. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds. Journal of Hypertension. 2005;23(1):7-17. Go to original source... Go to PubMed...
    18. Deban L, Correale C, Vetrano S, et al. Multiple Pathogenic Roles of Microvasculature in Inflammatory Bowel Disease: A Jack of All Trades. The American Journal of Pathology. 2008;172(6):1457-1466. Go to original source... Go to PubMed...
    19. Steyers C, Miller F. Endothelial Dysfunction in Chronic Inflammatory Diseases. IJMS. 2014;15(7):11324-11349. Go to original source... Go to PubMed...
    20. Sleutjes JAM, Van Lennep JER, Van Der Woude CJ, et al. Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management. Therap Adv Gastroenterol. 2021;14:175628482110321. Go to original source... Go to PubMed...
    21. Aksoy EK, Çetinkaya H, Savaş B, et al. Vascular endothelial growth factor, endostatin levels and clinical features among patients with ulcerative colitis and irritable bowel syndrome and among healthy controls: a cross-sectional analytical study. Sao Paulo Med J. 2018;136(6):543-550. Go to original source... Go to PubMed...
    22. Danese S, Semeraro S, Marini M, et al. Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation. Digestive and Liver Disease. 2005;37(11):811-818. Go to original source... Go to PubMed...
    23. Murch SH, Braegger CP, MacDonald TT, et al. High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. The Lancet. 1992;339(8790):381-385. Go to original source... Go to PubMed...
    24. Horowitz S, Binion DG, Nelson VM, et al. Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2007;292(5):G1323-1336. Go to original source... Go to PubMed...
    25. Garolla A, D'Incà R, Checchin D, et al. Reduced Endothelial Progenitor Cell Number and Function in Inflammatory Bowel Disease: A Possible Link to the Pathogenesis. Am J Gastroenterol. 2009;104(10):2500-2507. Go to original source... Go to PubMed...
    26. Magro DO, Kotze PG, Martinez CAR, et al. Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease. Intest Res. 2017;15(3):352. Go to original source... Go to PubMed...
    27. Esmon CT. The impact of the inflammatory response on coagulation. Thrombosis Research. 2004;114(5-6):321-327. Go to original source... Go to PubMed...
    28. Yoshida H, Granger ND. Inflammatory bowel disease: A paradigm for the link between coagulation and inflammation. Inflammatory Bowel Diseases. 2009;15(8):1245-1255. Go to original source... Go to PubMed...
    29. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut. 1993;34(2):247-251. Go to original source... Go to PubMed...
    30. Irving PM, Macey MG, Shah U, et al. Formation of Platelet-leukocyte Aggregates in Inflammatory Bowel Disease: Inflammatory Bowel Diseases. 2004;10(4):361-372. Go to original source... Go to PubMed...
    31. Andoh A, Yoshida T, Yagi Y, et al. Increased aggregation response of platelets in patients with inflammatory bowel disease. J Gastroenterol. 2006;41(1):47-54. Go to original source... Go to PubMed...
    32. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. The Lancet. 2010;375(9715):657-663. Go to original source... Go to PubMed...
    33. Fumery M, Xiaocang C, Dauchet L, et al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies. Journal of Crohn's and Colitis. 2014;8(6):469-479. Go to original source... Go to PubMed...
    34. Nguyen GC, Sam J. Rising Prevalence of Venous Thromboembolism and Its Impact on Mortality Among Hospitalized Inflammatory Bowel Disease Patients. The American Journal of Gastroenterology. 2008;103(9):2272-2280. Go to original source... Go to PubMed...
    35. Higgins PDR, Skup M, Mulani PM, et al. Increased Risk of Venous Thromboembolic Events With Corticosteroid vs Biologic Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology. 2015;13(2):316-321. Go to original source... Go to PubMed...
    36. Fleming F, Gaertner W, Ternent CA, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guideline for the Prevention of Venous Thromboembolic Disease in Colorectal Surgery. Diseases of the Colon & Rectum. 2018;61(1):14-20. Go to original source... Go to PubMed...
    37. Twig G, Zandman-Goddard G, Szyper-Kravitz M, et al. Systemic Thromboembolism in Inflammatory Bowel Disease: Mechanisms and Clinical Applications. Annals of the New York Academy of Sciences. 2005;1051(1):166-173. Go to original source... Go to PubMed...
    38. Landman C, Nahon S, Cosnes J, et al. Portomesenteric Vein Thrombosis in Patients With Inflammatory Bowel Disease: Inflammatory Bowel Diseases. 2013;19(3):582-589. Go to original source... Go to PubMed...
    39. Gala D, Newsome T, Roberson N, et al. Thromboembolic Events in Patients with Inflammatory Bowel Disease: A Comprehensive Overview. Diseases. 2022;10(4):73. Go to original source... Go to PubMed...
    40. Bernstein CN, Wajda A, Blanchard JF. The Incidence of Arterial Thromboembolic Diseases in Inflammatory Bowel Disease: A Population-Based Study. Clinical Gastroenterology and Hepatology. 2008;6(1):41-45. Go to original source... Go to PubMed...
    41. Richard S. Internal carotid thrombus in patients with inflammatory bowel disease: Two cases. WJG. 2013;19(5):773. Go to original source... Go to PubMed...
    42. Irving PM, Alstead EM, Greaves RR, et al. Acute mesenteric infarction: an important cause of abdominal pain in ulcerative colitis: European Journal of Gastroenterology & Hepatology. 2005;17(12):1429-1432. Go to original source... Go to PubMed...
    43. Lin TY, Chen YG, Lin CL, et al. Inflammatory Bowel Disease Increases the Risk of Peripheral Arterial Disease: A Nationwide Cohort Study. Medicine. 2015;94(52):e2381. Go to original source... Go to PubMed...
    44. Novacek G, Haumer M, Schima W, et al. Aortic Mural Thrombi in Patients With Inflammatory Bowel Disease: Report of Two Cases and Review of the Literature. Inflammatory Bowel Diseases. 2004;10(4):430-435. Go to original source... Go to PubMed...
    45. Aarestrup J, Jess T, Kobylecki CJ, et al. Cardiovascular Risk Profile Among Patients With Inflammatory Bowel Disease: A Population-based Study of More Than 100 000 Individuals. Journal of Crohn's and Colitis. 2019;13(3):319-323. Go to original source... Go to PubMed...
    46. Nazir S, Jankowski V, Bender G, et al. Interaction between high-density lipoproteins and inflammation: Function matters more than concentration! Advanced Drug Delivery Reviews. 2020;159:94-119. Go to original source... Go to PubMed...
    47. Cainzos-Achirica M, Glassner K, Zawahir HS, et al. Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology. 2020;76(24):2895-2905. Go to original source... Go to PubMed...
    48. Spence JD. Recent advances in pathogenesis, assessment, and treatment of atherosclerosis. F1000Res. 2016;5:1880. Go to original source... Go to PubMed...
    49. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205-217. Go to original source... Go to PubMed...
    50. Brzozowski B, Mazur-Bialy A, Pajdo R, et al. Mechanisms by which Stress Affects the Experimental and Clinical Inflammatory Bowel Disease (IBD): Role of Brain-Gut Axis. CN. 2016;14(8):892-900. Go to original source... Go to PubMed...
    51. To N, Gracie DJ, Ford AC. Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease. Aliment Pharmacol Ther. 2016;43(5):549-561. Go to original source... Go to PubMed...
    52. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. The Lancet. 2010;375(9709):132-140. Go to original source... Go to PubMed...
    53. Műzes G. Changes of the cytokine profile in inflammatory bowel diseases. WJG. 2012;18(41):5848. Go to original source... Go to PubMed...
    54. Abbate A, Toldo S, Marchetti C, et al. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res. 2020;126(9):1260-1280. Go to original source... Go to PubMed...
    55. Su JH, Luo MY, Liang N, et al. Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases. Front Pharmacol. 2021;12:745061. Go to original source... Go to PubMed...
    56. Szekely Y, Arbel Y. A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today? Cardiol Ther. 2018;7(1):25-44. Go to original source... Go to PubMed...
    57. Libby P, Simon DI. Inflammation and Thrombosis: The Clot Thickens. Circulation. 2001;103(13):1718-1720. Go to original source... Go to PubMed...
    58. deFonseka AM, Tuskey A, Conaway MR, et al. Antitumor Necrosis Factor-α Therapy Is Associated With Reduced Risk of Thromboembolic Events in Hospitalized Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology. 2016;50(7):578-583. Go to original source... Go to PubMed...
    59. Bollen L, Vande Casteele N, Peeters M, et al. Short-term Effect of Infliximab Is Reflected in the Clot Lysis Profile of Patients with Inflammatory Bowel Disease: A Prospective Study. Inflammatory Bowel Diseases. 2015;21(3):570-578. Go to original source... Go to PubMed...
    60. Levi M, Van Der Poll T, Büller HR. Bidirectional Relation Between Inflammation and Coagulation. Circulation. 2004;109(22):2698-2704. Go to original source... Go to PubMed...
    61. Witkowski M, Weeks TL, Hazen SL. Gut Microbiota and Cardiovascular Disease. Circ Res. 2020;127(4):553-570. Go to original source... Go to PubMed...
    62. Khan I, Ullah N, Zha L, et al. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens. 2019;8(3):126. Go to original source... Go to PubMed...
    63. Khorsand B, Asadzadeh Aghdaei H, Nazemalhosseini-Mojarad E, et al. Overrepresentation of Enterobacteriaceae and Escherichia coli is the major gut microbiome signature in Crohn's disease and ulcerative colitis; a comprehensive metagenomic analysis of IBDMDB datasets. Front Cell Infect Microbiol. 2022;12:1015890. Go to original source... Go to PubMed...
    64. Amiri P, Hosseini SA, Ghaffari S, et al. Role of Butyrate, a Gut Microbiota Derived Metabolite, in Cardiovascular Diseases: A comprehensive narrative review. Front Pharmacol. 2022;12:837509. Go to original source... Go to PubMed...
    65. Ferrer-Picón E, Dotti I, Corraliza AM, et al. Intestinal Inflammation Modulates the Epithelial Response to Butyrate in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2020;26(1):43-55. Go to original source... Go to PubMed...
    66. Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275-1283. Go to original source... Go to PubMed...
    67. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006;24(s1):2-9. Go to original source... Go to PubMed...
    68. Pujades-Rodriguez M, Morgan AW, Cubbon RM, et al. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. Rahimi K, editor. PLoS Med. 2020;17(12):e1003432. Go to original source... Go to PubMed...
    69. Dheyriat L, Ward D, Beaugerie L, et al. Risk of Recurrent Acute Arterial Events Associated With Thiopurines and Anti-Tumor Necrosis Factor in Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology. 2023;21(1):164-172.e11. Go to original source... Go to PubMed...
    70. Woodman RJ, Baghdadi LR, Shanahan ME, et al. The Temporal Relationship between Arterial Stiffening and Blood Pressure Is Modified by Methotrexate Treatment in Patients with Rheumatoid Arthritis. Front Physiol. 2017;8:593. Go to original source... Go to PubMed...
    71. Sandborn WJ, Rebuck R, Wang Y, et al. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clinical Gastroenterology and Hepatology. 2022;20(3):578-590.e4. Go to original source... Go to PubMed...
    72. Singh S, Iversen AT, Allin KH, et al. Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases. JAMA Netw Open. 2022;5(9):e2234200. Go to original source... Go to PubMed...
    73. Koutroubakis IE, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease: European Journal of Gastroenterology & Hepatology. 2009;21(3):283-288. Go to original source... Go to PubMed...
    74. Miranda-Bautista J, De Gracia-Fernández C, López-Ibáñez M, et al. Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy. Dig Dis Sci. 2015;60(7):2130-2135. Go to original source... Go to PubMed...
    75. Parmentier-Decrucq E, Duhamel A, Ernst O, et al. Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohnʼs disease: Inflammatory Bowel Diseases. 2009;15(10):1476-1484. Go to original source... Go to PubMed...
    76. Paschou SA, Kothonas F, Lafkas A, et al. Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease. International Journal of Endocrinology. 2018;2018:1-5. Go to original source... Go to PubMed...
    77. Sands BE, Taub PR, Armuzzi A, et al. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2020;18(1):123-132.e3. Go to original source... Go to PubMed...
    78. Sands BE, Colombel JF, Ha C, et al. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management. Inflammatory Bowel Diseases. 2021;27(6):797-808. Go to original source... Go to PubMed...
    79. Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1554-1573.e12. Go to original source... Go to PubMed...
    80. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42(34):3227-3337. Go to original source... Go to PubMed...
    81. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17-28. Go to original source... Go to PubMed...
    82. Singh S, Singh H, Loftus EV, et al. Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 2014;12(3):382-393.e1. Go to original source... Go to PubMed...
    83. Bewtra M, Kaiser LM, TenHave T, et al. Crohn's Disease and Ulcerative Colitis Are Associated With Elevated Standardized Mortality Ratios: A Meta-Analysis. Inflammatory Bowel Diseases. 2013;19(3):599-613. Go to original source... Go to PubMed...

    Return to the content